Leonard B Saltz

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Systemic therapy for metastatic colorectal cancer
    Leonard Saltz
    Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Natl Compr Canc Netw 11:649-52. 2013
  2. doi request reprint Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer
    Leonard Saltz
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 11:101-11. 2012
  3. ncbi request reprint The camptothecins
    Joseph F Pizzolato
    Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology Service, 1275 York Avenue, New York, NY 10021, USA
    Lancet 361:2235-42. 2003
  4. ncbi request reprint Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study
    Leonard B Saltz
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4557-61. 2007
  5. doi request reprint Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 917, New York, NY 10021, USA
    J Clin Oncol 26:2013-9. 2008
  6. ncbi request reprint Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    Leonard B Saltz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1201-8. 2004
  7. doi request reprint Adjuvant therapy for colon cancer
    Leonard B Saltz
    Colorectal Oncology Section, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Surg Oncol Clin N Am 19:819-27. 2010
  8. ncbi request reprint Palliative management of rectal cancer: the roles of chemotherapy and radiation therapy
    Leonard B Saltz
    Colorectal Disease Management Team, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Gastrointest Surg 8:274-6. 2004
  9. ncbi request reprint Evolving treatment of advanced colon cancer
    Neil H Segal
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Annu Rev Med 60:207-19. 2009
  10. ncbi request reprint Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors
    L B Saltz
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 14:2959-67. 1996

Detail Information

Publications106 found, 100 shown here

  1. ncbi request reprint Systemic therapy for metastatic colorectal cancer
    Leonard Saltz
    Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Natl Compr Canc Netw 11:649-52. 2013
    ..However, he also noted that statistical significance does not necessarily equal clinical significance, and indicated that clinicians should consider the differential toxicity profiles of the regimens when individualizing treatment...
  2. doi request reprint Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer
    Leonard Saltz
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 11:101-11. 2012
    ....
  3. ncbi request reprint The camptothecins
    Joseph F Pizzolato
    Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology Service, 1275 York Avenue, New York, NY 10021, USA
    Lancet 361:2235-42. 2003
    ..As knowledge of molecular and biochemical mechanisms of action and resistance continues to expand, newer and better camptothecin-based strategies for treatment of malignant disease are likely to evolve...
  4. ncbi request reprint Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study
    Leonard B Saltz
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4557-61. 2007
    ..We evaluated the safety and efficacy of concurrent administration of two monoclonal antibodies, cetuximab and bevacizumab, in patients with metastatic colorectal cancer...
  5. doi request reprint Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 917, New York, NY 10021, USA
    J Clin Oncol 26:2013-9. 2008
    ....
  6. ncbi request reprint Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    Leonard B Saltz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1201-8. 2004
    ..To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor...
  7. doi request reprint Adjuvant therapy for colon cancer
    Leonard B Saltz
    Colorectal Oncology Section, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Surg Oncol Clin N Am 19:819-27. 2010
    ..Stage III colorectal cancer (TanyN₁₋₂M₀) represents a group at a higher risk of recurrence, and this population is routinely given adjuvant chemotherapy in the absence of a medical or psychiatric contraindication...
  8. ncbi request reprint Palliative management of rectal cancer: the roles of chemotherapy and radiation therapy
    Leonard B Saltz
    Colorectal Disease Management Team, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Gastrointest Surg 8:274-6. 2004
    ..A discussion of palliative care in a patient with rectal cancer must therefore be based on the assumption that the patient does not have a realistic chance of undergoing a curative intervention...
  9. ncbi request reprint Evolving treatment of advanced colon cancer
    Neil H Segal
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Annu Rev Med 60:207-19. 2009
    ..We present in detail these recent advances and provide some insight into several promising future strategies...
  10. ncbi request reprint Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors
    L B Saltz
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 14:2959-67. 1996
    ....
  11. ncbi request reprint Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:3456-61. 2007
    ..We evaluated the efficacy and safety of weekly bolus CPT-11 plus FU plus LV in the treatment of patients with completely resected stage III colon cancer...
  12. ncbi request reprint Metastatic colorectal cancer: is there one standard approach?
    Leonard B Saltz
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 19:1147-54; discussion 1154, 1157-8, 1160. 2005
    ..role for continuing bevacizumab in subsequent regimens? Is there a role for cetuximab (Erbitux) in standard first-line chemotherapy? Are there practices in colorectal cancer that have become widely accepted without direct supportive data?..
  13. ncbi request reprint Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 2:20-1. 2005
  14. ncbi request reprint Adjuvant treatment of colorectal cancer
    L B Saltz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Annu Rev Med 48:191-202. 1997
    ..We examine in detail the data on which current recommendations for adjuvant treatments are based. We also review some of the more promising experimental approaches currently under investigation...
  15. ncbi request reprint Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?
    Leonard Saltz
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Colorectal Cancer 5:S98-100. 2005
    ..No patient should be refused treatment with an EGFR-targeting agent solely on the basis of a negative EGFR IHC test and no patient should be given anti-EGFR therapy simply on the basis of a positive or strongly positive EGFR test result...
  16. ncbi request reprint Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors
    L B Saltz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:3858-65. 1998
    ..In vitro synergy between cisplatin and irinotecan (CPT-11) has been reported. We designed a combination schedule of these agents to maximize the potential for synergistic interaction...
  17. ncbi request reprint Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard
    L B Saltz
    Memorial Sloan Kettering Hospital, New York, New York, USA
    Oncologist 6:81-91. 2001
    ..S. and European approval of irinotecan/5-FU/LV for this indication. An overview of the findings of these two pivotal studies provides insights regarding the application of this new combination in clinical practice...
  18. ncbi request reprint Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:4793-9. 2007
    ..We assessed the safety and efficacy of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy...
  19. ncbi request reprint Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial
    Deborah Schrag
    All authors Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 32:513-8. 2014
    ..We evaluated preoperative infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/bevacizumab with selective rather than consistent use of chemoradiotherapy...
  20. ncbi request reprint Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome
    George A Poultsides
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:2797-804. 2012
    ..Histologically, dominant response patterns include fibrosis, necrosis and/or acellular mucin, but some of these changes can appear without previous chemotherapy and their individual correlation with outcome is unknown...
  21. doi request reprint Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Invest 27:402-6. 2009
    ..We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan...
  22. doi request reprint Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation
    Hak Mien Quah
    Department of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 113:57-64. 2008
    ....
  23. ncbi request reprint Surgery and high-dose-rate intraoperative radiation therapy for recurrent squamous-cell carcinoma of the anal canal
    Jean L Wright
    Department of Radiation Oncology, University of Miami, Miami, Florida, USA
    Dis Colon Rectum 54:1090-7. 2011
    ..Locoregionally recurrent squamous-cell carcinoma of the anal canal is managed with salvage surgery. High-dose-rate intraoperative radiation therapy has been used in selected patients with this disease to reduce the risk of local recurrence...
  24. ncbi request reprint Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study
    Jose G Guillem
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 258:289-95. 2013
    ..To prospectively compare the ability of flourodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) to identify a pathological complete response (pCR) in patients with rectal cancer treated by chemoradiation...
  25. doi request reprint FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation
    Jeannine A Ruby
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Dis Colon Rectum 55:378-86. 2012
    ..At present there is no defined role for routine FDG-PET in the preoperative evaluation of nonmetastatic rectal cancer...
  26. doi request reprint Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis
    Tobias Leibold
    Department of Surgery Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:2783-9. 2011
    ..We prospectively evaluated tumor response with (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) early in the course of preoperative CRT...
  27. ncbi request reprint Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
    Ghassan K Abou-Alfa
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    JAMA 304:2154-60. 2010
    ..The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial...
  28. doi request reprint Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision
    Anand Govindarajan
    Department of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:3666-72. 2011
    ..Patients with pathologically node-negative tumors have an improved prognosis, but recurrence patterns and independent prognostic factors in these patients have been incompletely characterized...
  29. pmc Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment
    George A Poultsides
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:3379-84. 2009
    ....
  30. doi request reprint Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy
    James D Smith
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 256:965-72. 2012
    ....
  31. doi request reprint Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer
    Jean M Butte
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 118:5414-23. 2012
    ..In this study, the authors examined recurrence patterns and survival after resection of SLMRC...
  32. doi request reprint A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
    Diane L Reidy-Lagunes
    Department of Medicine, Division of Solid Tumors, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:4795-800. 2012
    ..Therefore, the authors of this report evaluated the safety and efficacy of MK-0646, a fully human monoclonal antibody (MoAb) that binds to the IGF-1R, as monotherapy in patients with metastatic, well-differentiated NETs...
  33. pmc Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
    William P Tew
    Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 27:366-73. 2009
    ..To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies...
  34. ncbi request reprint Adjuvant therapy of colon cancer: current status and future directions
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021 and Weill Medical College of Cornell University, Ithaca, USA
    Cancer J 13:192-7. 2007
    ....
  35. ncbi request reprint Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 32:719-31. 2008
    ..These tumors are clinically aggressive. Prospective studies using defined diagnostic criteria are needed to determine their biologic characteristics and optimal management...
  36. ncbi request reprint Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, York, NY 10022, USA
    J Clin Oncol 24:4293-300. 2006
    ..This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients...
  37. doi request reprint Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer
    Andrea Cercek
    Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Colorectal Cancer 12:163-7. 2013
    ..We evaluated the incidence of FOLFOX-induced amenorrhea in women age 50 and younger treated with adjuvant therapy for colorectal cancer...
  38. ncbi request reprint Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease
    Garrett M Nash
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 9:954-60. 2002
    ..We have reviewed stage IV rectal cancer patients to evaluate the effectiveness of radical surgery without radiation as local therapy...
  39. ncbi request reprint Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study
    Michael D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 14:759-65. 2007
    ..Perioperative bev is now commonly used in patients undergoing hepatic resection. Little is known, however, about the safety of perioperative bev use in the setting of hepatic resection...
  40. pmc Comparative genomic analysis of primary versus metastatic colorectal carcinomas
    Efsevia Vakiani
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 30:2956-62. 2012
    ..To compare the mutational and copy number profiles of primary and metastatic colorectal carcinomas (CRCs) using both unpaired and paired samples derived from primary and metastatic disease sites...
  41. doi request reprint Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning
    Jean L Wright
    Department of Radiation Oncology, University of Miami, Miami, FL 33133, USA
    Int J Radiat Oncol Biol Phys 78:1064-72. 2010
    ..To better define the CTV for IMRT, we evaluated patterns and predictors of LRF in SCCAC patients given conventional radiation treatment...
  42. ncbi request reprint Adjuvant therapy of cancers of the colon and rectum
    Leonard B Saltz
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Surg Clin North Am 82:1035-58. 2002
    ..Participation of eligible patients in clinical trials must continue to be actively encouraged. Only in this way will we be able to continue to build and expand on the progress that has been made thus far...
  43. doi request reprint Individualized prediction of colon cancer recurrence using a nomogram
    Martin R Weiser
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:380-5. 2008
    ..Although easy to implement, there remains significant heterogeneity within each stage grouping. In the era of multimodality treatment, a more refined tool is needed to predict recurrence...
  44. doi request reprint Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis
    Tina Dasgupta
    Department of Radiation Oncology, University of California San Francisco, CA, USA
    Radiother Oncol 107:189-94. 2013
    ..We compared IMRT and conventional radiotherapy (CRT) outcomes in ASCC patients...
  45. ncbi request reprint Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:1857-62. 2006
    ..Two antibodies, the PharmDx kit and the 31G7 clone, are used commonly for immunohistochemistry by various laboratories. No comparative studies on the performance of these 2 antibodies are available...
  46. pmc Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer
    Diane Lauren Reidy
    Department of Medicine, Division of Solid Tumors, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 1004, New York, NY 10065, USA
    J Clin Oncol 28:4240-6. 2010
    ....
  47. ncbi request reprint Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer
    Matthew S Katz
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 62:1363-70. 2005
    ..To assess whether 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, might enhance the efficacy of neoadjuvant chemoradiation in rectal cancer...
  48. ncbi request reprint Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, H 816, New York, NY 10021, USA
    J Clin Oncol 23:1803-10. 2005
    ....
  49. ncbi request reprint Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer
    Jose G Guillem
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 199:1-7. 2004
    ..Our goal was to determine the prognostic significance of FDG-PET assessment of rectal cancer response to preoperative chemoradiation...
  50. ncbi request reprint Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803
    Robert S Warren
    Authors Affiliations Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California Department of Biostatistics and Bioinformatics, Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina Dana Farber Cancer Institute Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts The Ohio State University, Columbus, Ohio National Cancer Institute, Bethesda, Maryland and Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 19:5777-87. 2013
    ..We investigated whether mutations in the DNA-binding domain of TP53 are associated with survival in stage III colon cancer...
  51. ncbi request reprint Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer
    Andrea Cercek
    From the aGastrointestinal Oncology Service, Department of Medicine, bDepartment of Radiation Therapy, and cColorectal Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    J Natl Compr Canc Netw 12:513-9. 2014
    ..FOLFOX and chemoradiation before planned TME results in tumor regression, a high rate of delivery of planned therapy, and a substantial rate of pathCRs, and offers a good platform for nonoperative management in select patients. ..
  52. ncbi request reprint Bevacizumab 5 mg/kg can be infused safely over 10 minutes
    Diane L Reidy
    Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2691-5. 2007
    ..We sought to determine if the initial prolonged infusion was still necessary and if an infusion time of fewer than 30 minutes could be safely used...
  53. ncbi request reprint First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents
    Andrea Cercek
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Colorectal Cancer 7:S47-51. 2008
    ..However, these agents are not without substantial potential for toxicity. This review will discuss the available therapies and the data to justify the appropriate use and nonuse of targeted therapies in patients with metastatic CRC...
  54. pmc Genomic and biological characterization of exon 4 KRAS mutations in human cancer
    Manickam Janakiraman
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 70:5901-11. 2010
    ..These results also provide a rationale for broader KRAS testing beyond the most common hotspot alleles in exons 2 and 3...
  55. ncbi request reprint Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome
    Harvey G Moore
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 1077, New York, NY 10021, USA
    Ann Surg Oncol 11:955-61. 2004
    ..Although numerous studies have focused on identifying molecular markers of prognosis in the primary rectal cancer before CMT, our aim was to identify markers of prognosis in residual rectal cancer after preoperative CMT...
  56. pmc A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Internal Medicine, Weill Medical College at Cornell University, New York, NY, United States Electronic address
    J Hepatol 60:319-24. 2014
    ..IGF-IR is implicated in hepatic carcinogenesis. This and preliminary evidence of biological activity of anti-IGF-1R monoclonal antibody cixutumumab in phase I trials prompted this phase II study...
  57. ncbi request reprint Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors
    Jeremy Kortmansky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1875-84. 2005
    ..We designed a phase I clinical trial of FU in combination with UCN-01...
  58. doi request reprint Progress in cancer care: the hope, the hype, and the gap between reality and perception
    Leonard B Saltz
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, NY, USA
    J Clin Oncol 26:5020-1. 2008
  59. ncbi request reprint Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors
    Kyle D Holen
    Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology Service, Department of Medicine, New York, NY 10021, USA
    J Clin Oncol 20:4673-8. 2002
    ..Acinar cell carcinoma is a rare tumor of the exocrine pancreas. Clinical features such as prognostic information, survival, and treatment outcomes are unknown. We present the largest retrospective review to date...
  60. ncbi request reprint A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol
    Manish A Shah
    Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 11:3836-45. 2005
    ..We initiated a phase I trial of the sequential combination of irinotecan followed by flavopiridol to determine the maximal tolerated dose of this combination therapy...
  61. ncbi request reprint Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Bronx, NY, USA
    J Clin Oncol 23:5235-46. 2005
    ..The cause of the possible relationship between rash and clinical benefit remains unclear at this time, and additional studies are needed to determine the clinical utility of this observation...
  62. ncbi request reprint BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
    Rona Yaeger
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 120:2316-24. 2014
    ....
  63. ncbi request reprint Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach?
    Martin R Weiser
    Colorectal Service Dept of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncology (Williston Park) 27:1074-8. 2013
    ..Here we present the insights we have arrived at through our own considerable experience with this patient population, and we reflect on the relevant studies that are available...
  64. doi request reprint Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature
    Yevgeniy Karamurzin
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hum Pathol 43:1677-87. 2012
    ..As yet, however, there are no data to support the inclusion of these tumors into general screening guidelines for detecting Lynch syndrome, nor are there data to warrant surveillance for these tumors in patients with Lynch syndrome...
  65. ncbi request reprint Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors
    Diane L Reidy
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
    Nat Clin Pract Oncol 6:143-52. 2009
    ..We will discuss the data on therapies currently used to treat well-differentiated NETs, and the strategies being used in clinical trials...
  66. ncbi request reprint Irinotecan (Campto) in the treatment of pancreatic cancer
    Joseph F Pizzolato
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Expert Rev Anticancer Ther 3:587-93. 2003
    ..A promising combination of irinotecan with oxaliplatin (Eloxatin) and fluorouracil will be assessed in a Phase III study...
  67. ncbi request reprint Antibody-based therapies for colorectal cancer
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 10:701-9. 2005
    ..South San Francisco, CA, http://www.gene.com) and cetuximab (Erbitux; ImClone Systems, Inc., New York, http://www.imclone.com), in colorectal cancer...
  68. ncbi request reprint Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection
    Harvey G Moore
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 47:279-86. 2004
    ..Prolongation of the interval between preoperative combined modality therapy and surgery (RT-surgery interval) as a means of increasing pathologic complete response rate has not been fully examined...
  69. doi request reprint BEYOND KRAS: Other markers and potential treatment strategies for KRAS mutant and wild-type patients
    Andrea Cercek
    Colorectal Oncology Section, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 264, New York, NY 10065, USA
    Curr Treat Options Oncol 12:126-35. 2011
    ..As our molecular knowledge of mcrc advances future therapies will likely tailor an individualized approach based on tumor specific molecular markers...
  70. ncbi request reprint Cetuximab therapy and symptomatic hypomagnesemia
    Deborah Schrag
    Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 221, New York, NY 10011, USA
    J Natl Cancer Inst 97:1221-4. 2005
    ..Because symptoms may be rapidly ameliorated with supplementation, we suggest that, when fatigue or hypocalcemia is encountered during cetuximab therapy, serum magnesium level be measured and repleted as necessary...
  71. doi request reprint Evolving treatment of advanced colorectal cancer
    Andrea Cercek
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room H 917, New York, NY 10065, USA
    Curr Oncol Rep 12:153-9. 2010
    ..This review discusses the available therapies in metastatic colorectal cancer and describes some of the molecular markers implicated in activity and resistance to current targeted therapies...
  72. ncbi request reprint Developing a cancer-specific geriatric assessment: a feasibility study
    Arti Hurria
    Department of Medicine, Psychiatry and Behavioral Sciences, and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1998-2005. 2005
    ....
  73. pmc Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer
    Jose G Guillem
    Department of Surgery Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 241:829-36; discussion 836-8. 2005
    ....
  74. ncbi request reprint Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
    Gary K Schwartz
    Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Section, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2157-70. 2002
    ..We therefore designed a phase I clinical trial of sequential paclitaxel and flavopiridol...
  75. ncbi request reprint Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point
    Jose G Guillem
    Colorectal Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 1077, New York, NY 10021, USA
    J Clin Oncol 23:3475-9. 2005
    ..However, because the accuracy of this approach has not been established, we conducted a prospective analysis to determine the operating surgeon's ability to assess response using DRE...
  76. ncbi request reprint Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 18:1350-6. 2005
    ..Additional studies are needed to determine whether epidermal growth factor receptor gene amplification bears any informative value in predicting response to cetuximab-based therapy...
  77. ncbi request reprint Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Anticancer Drugs 15:219-27. 2004
    ..0 mg/m, with manageable toxicity. This combination shows encouraging activity, and survival appears promising in the pre-treated aCRC patient population. Further clinical trials are warranted...
  78. ncbi request reprint Understanding and managing chemotherapy-induced diarrhea
    Leonard B Saltz
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Support Oncol 1:35-46; discussion 38-41, 45-6. 2003
    ..Early recognition of diarrhea and early pharmacologic intervention can greatly facilitate successful resolution of this treatment complication...
  79. ncbi request reprint Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service
    David B Chessin
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 200:876-82; discussion 882-4. 2005
    ..But its impact on postoperative complications has not been adequately evaluated. Our aims were to evaluate our comprehensive experience and identify factors predictive of complications in this patient population...
  80. ncbi request reprint Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?
    Ramesh Rengan
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:4905-12. 2005
    ....
  81. ncbi request reprint Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption
    Alon Scope
    Dermatology Service and Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    J Clin Oncol 25:5390-6. 2007
    ..To evaluate the ability of either oral minocycline, topical tazarotene or both, to reduce or prevent cetuximab-related acneiform rash when administered starting on day 1 of cetuximab therapy...
  82. ncbi request reprint Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy
    Harvey G Moore
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 10:80-5. 2003
    ..To further define the subset of rectal cancer patients suitable for this approach, we determined the adequacy of a distal margin of < or = 1 cm in patients with locally advanced rectal cancer requiring preoperative CMT...
  83. pmc Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy
    Leyo Ruo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 236:75-81. 2002
    ....
  84. ncbi request reprint Use of surgery among elderly patients with stage IV colorectal cancer
    Larissa K F Temple
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:3475-84. 2004
    ..The purpose of this study was to evaluate surgical practice patterns for patients > or = 65 years of age with stage IV CRC in a US population-based cohort...
  85. ncbi request reprint Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders
    Ramesh Rengan
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 5:413-21. 2006
    ..The primary objective of this study was to determine the long-term outcome of sphincter preservation with preoperative radiation therapy (RT) and surgical resection in the treatment of distal rectal adenocarcinoma...
  86. ncbi request reprint Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients
    Spiros P Hiotis
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    J Am Coll Surg 194:131-5; discussion 135-6. 2002
    ..Some investigators have proposed that such patients should simply be observed and not undergo resection...
  87. ncbi request reprint Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer
    Ki Y Chung
    Gastrointestinal Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:3485-90. 2010
    ..Safety and efficacy of tremelimumab (CP-675,206), a fully human anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) monoclonal antibody, were assessed in patients with treatment-refractory colorectal cancer...
  88. pmc Current management of advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, NY
    Gastrointest Cancer Res 2:64-70. 2008
    ..The innovative therapeutic outcomes associated with novel targeted therapies illustrates the need for biologic and pharmacokinetic end points to define their optimal doses and therapeutic effects...
  89. ncbi request reprint ACR Appropriateness Criteria on treatment of anal cancer
    Matthew M Poggi
    National Naval Medical Center, Department of Radiation Oncology, Bethesda, Md 20889 5000, USA
    J Am Coll Radiol 4:448-56. 2007
    ..To this end, anal cancer is a disease best treated primarily with chemoradiation. Although appropriate treatment can produce acceptable results, further investigation and improvement in therapy are still needed...
  90. ncbi request reprint Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer
    Deborah Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:3999-4005. 2002
    ..Nevertheless, patients may receive this treatment despite its uncertain benefit. The objective of this study was to determine the extent to which adjuvant chemotherapy is used for patients with stage II colon cancer...
  91. ncbi request reprint Targeted strategies in the treatment of metastatic colon cancer
    Diane Reidy
    Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 5:983-90. 2007
    ..Finally, some newer drugs and strategies currently being tested in clinical trials are discussed...
  92. ncbi request reprint Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy
    Robert P Akbari
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Dis Colon Rectum 47:1136-44. 2004
    ..Primary chemoradiation failure for epidermoid carcinoma of the anus is treated by surgical resection. This study evaluates the outcome of salvage surgery at one institution...
  93. ncbi request reprint Planned treatment interruptions and chemotherapy-free intervals in the treatment of metastatic colorectal cancer: time to start stopping?
    Leonard Saltz
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 33:S28-32. 2006
    ..This article will address these and other trials, as well as data relating to incorporation of biologic therapies into combination chemotherapy for patients with advanced colorectal cancer...
  94. doi request reprint A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption
    Alon Scope
    Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    J Am Acad Dermatol 61:614-20. 2009
    ..Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking...
  95. doi request reprint ACR Appropriateness Criteria on resectable rectal cancer: expert panel on radiation oncology--rectal/anal cancer
    W Warren Suh
    Department of Radiation Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA 02459, USA
    Int J Radiat Oncol Biol Phys 70:1427-30. 2008
    ..A summary of the major randomized clinical trials spanning the past several decades is provided...
  96. ncbi request reprint Systemic therapy for colon cancer
    Timothy R Asmis
    Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gastroenterol Clin North Am 37:287-95, ix. 2008
    ..There have been many advances in the surgical and medical treatment of CRC over the last 10 years. This article reviews the indications, efficacy, and toxicity of chemotherapy and targeted therapy for patients who have CRC...
  97. ncbi request reprint Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 298:754-64. 2007
    ..Dietary factors have been associated with the risk of developing colon cancer but the influence of diet on patients with established disease is unknown...
  98. ncbi request reprint The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
    Kyle Holen
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University Hospital and Clinics, 600 Highland Ave K4 528, Madison, WI 53792, USA
    Invest New Drugs 26:45-51. 2008
    ..FK866 is a potent inhibitor or NAD synthesis. This first-in-human study was performed to determine the maximum-tolerated dose, toxicity profile, and pharmacokinetics on a 96-h continuous infusion schedule...
  99. ncbi request reprint Another study of how to give fluorouracil?
    Leonard B Saltz
    J Clin Oncol 21:3711-2. 2003
  100. ncbi request reprint A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum
    Melanie E Royce
    The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Invest New Drugs 22:53-61. 2004
    ..To evaluate the antitumor activity, toxicities, and pharmacokinetics (PK) of DX-8951f administered as a 30-min infusion daily for 5 days every 3 weeks in patients with fluorouracil-resistant metastatic colorectal carcinoma...
  101. ncbi request reprint Potential regional differences for the tolerability profiles of fluoropyrimidines
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:2118-23. 2008
    ....